- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Bachelot Spotlights Impact of Tucatinib for CNS Metastases in HER2+ Breast Cancer
May 8th 2021, 10:29am
Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.
Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer
May 8th 2021, 1:02am
Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.
Dr. Voorwerk on Outcomes with Atezolizumab Plus Carboplatin in Metastatic Lobular Breast Cancer
May 7th 2021, 10:16pm
Leonie Voorwerk, discusses outcomes with the combination of atezolizumab plus carboplatin in metastatic lobular breast cancer, which was evaluated as part of the phase 2 GELATO trial.
Dr. Bachelot on the Role of Tucatinib in HER2+ Breast Cancer With CNS Metastases
May 7th 2021, 9:42pm
Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.
Ribociclib/Endocrine Therapy Improves OS Regardless of Age in Advanced HR+/HER2- Breast Cancer
May 7th 2021, 9:08pm
Ribociclib plus endocrine therapy improved overall survival and post-progression outcomes in pre- or postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer irrespective of age.
Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer
May 7th 2021, 5:30pm
Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.
Breast Cancer Survivors Need More Tailored Follow-Up Care
May 7th 2021, 2:09pm
Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.
Addition of SDX-7320 to Palbociclib Inhibits Tumor Growth in Breast Cancer Xenografts
April 15th 2021, 8:55pm
The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.
Ahuno on Bringing Precision Medicine in Cancer Care to Ghana
April 14th 2021, 11:40pm
Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.
Dr. Matasar on the Efficacy of Copanlisib Plus Rituximab in Indolent NHL
April 14th 2021, 11:31pm
Matthew J. Matasar, MD, discusses the efficacy of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.
Triplet Combos Targeting ER, CDK4/6, and PIK3CA Inhibit Tumor Growth in ER+ Breast Cancer
April 14th 2021, 8:10pm
A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.
cfDNA Sequencing Shows Utility in Selecting KRAS G12C+ NSCLC for Sotorasib
April 14th 2021, 1:00pm
Plasma-based cell-free DNA appears to be a viable strategy comparable with tissue-based testing for selecting patients with KRAS G12C–mutant non–small cell lung cancer for treatment with sotorasib.
Dr. Hassan on the Rationale for Examining Talazoparib Plus Carboplatin in TNBC
April 14th 2021, 12:31pm
Saima Hassan, MD, PhD, FRCSC, discusses the rationale for examining talazoparib in combination with carboplatin in patients with triple-negative breast cancer.
Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers
April 13th 2021, 11:30pm
Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.
Neoadjuvant Cemiplimab Elicits Complete Pathological Responses in HCC
April 13th 2021, 10:26pm
Significant tumor necrosis was observed in 20% of patients with resectable hepatocellular carcinoma who received neoadjuvant treatment with cemiplimab-rwlc.
Trastuzumab Deruxtecan Benefit/Risk Profile in Advanced Cancer Supported by Pooled Analysis
April 13th 2021, 6:47pm
The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.
Atezolizumab Induces Durable Activity Irrespective of MSI Status in Advanced Solid Tumors With TMB ≥16 Mut/Mb
April 13th 2021, 5:44pm
Atezolizumab elicited durable clinical activity irrespective of microsatellite instability status in patients with advanced solid tumors with a tumor mutational burden of more than 16 mutations per megabase.
AFM13 Showcases 100% ORR in Relapsed/Refractory CD30+ Hodgkin Lymphoma
April 13th 2021, 3:30pm
AFM13, an innate cell engager, demonstrated an objective response rate of 100% in adult patients with CD30-positive, relapsed/refractory Hodgkin lymphoma.
Multi-Omics Approach to Personalized Therapy Shows Feasibility in Metastatic Breast Cancer
April 13th 2021, 2:54pm
A multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data has demonstrated feasibility in patients metastatic breast cancer vs DNA sequencing alone.
Telisotuzumab Vedotin Demonstrates Efficacy and Tolerability in Previously Treated c-MET+ NSCLC
April 13th 2021, 1:05pm
Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer.